Ionis Pharmaceuticals (IONS) – Research Analysts’ Recent Ratings Changes

A number of firms have modified their ratings and price targets on shares of Ionis Pharmaceuticals (NASDAQ: IONS) recently:

  • 2/8/2024 – Ionis Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
  • 2/1/2024 – Ionis Pharmaceuticals had its price target raised by analysts at JPMorgan Chase & Co. from $52.00 to $55.00. They now have a “neutral” rating on the stock.
  • 1/31/2024 – Ionis Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
  • 1/26/2024 – Ionis Pharmaceuticals had its price target raised by analysts at Royal Bank of Canada from $65.00 to $70.00. They now have an “outperform” rating on the stock.
  • 1/23/2024 – Ionis Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
  • 1/18/2024 – Ionis Pharmaceuticals had its price target raised by analysts at Piper Sandler from $60.00 to $62.00. They now have an “overweight” rating on the stock.
  • 1/15/2024 – Ionis Pharmaceuticals was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
  • 1/3/2024 – Ionis Pharmaceuticals was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
  • 1/2/2024 – Ionis Pharmaceuticals was upgraded by analysts at Bank of America Co. from a “neutral” rating to a “buy” rating. They now have a $62.00 price target on the stock, up previously from $52.00.
  • 12/19/2023 – Ionis Pharmaceuticals had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $60.00 price target on the stock.
  • 12/18/2023 – Ionis Pharmaceuticals had its price target raised by analysts at Stifel Nicolaus from $45.00 to $50.00. They now have a “hold” rating on the stock.

Ionis Pharmaceuticals Stock Down 2.0 %

IONS stock opened at $50.38 on Tuesday. The company has a debt-to-equity ratio of 4.06, a quick ratio of 6.33 and a current ratio of 6.39. The business’s 50-day moving average is $50.81 and its two-hundred day moving average is $46.53. The company has a market cap of $7.23 billion, a price-to-earnings ratio of -17.55 and a beta of 0.46. Ionis Pharmaceuticals, Inc. has a fifty-two week low of $32.69 and a fifty-two week high of $54.44.

Insider Buying and Selling

In related news, CFO Elizabeth L. Hougen sold 2,125 shares of the stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $49.54, for a total transaction of $105,272.50. Following the completion of the sale, the chief financial officer now owns 92,905 shares in the company, valued at $4,602,513.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director B Lynne Parshall sold 25,113 shares of the firm’s stock in a transaction that occurred on Tuesday, December 26th. The stock was sold at an average price of $51.46, for a total value of $1,292,314.98. Following the completion of the sale, the director now directly owns 82,588 shares of the company’s stock, valued at approximately $4,249,978.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Elizabeth L. Hougen sold 2,125 shares of the firm’s stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $49.54, for a total value of $105,272.50. Following the completion of the sale, the chief financial officer now directly owns 92,905 shares of the company’s stock, valued at $4,602,513.70. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 239,810 shares of company stock worth $12,108,463. 2.65% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Ionis Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Ionis Pharmaceuticals by 3.3% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 50,585 shares of the company’s stock valued at $1,874,000 after acquiring an additional 1,604 shares during the period. American Century Companies Inc. purchased a new position in Ionis Pharmaceuticals during the 1st quarter worth $207,000. US Bancorp DE grew its stake in Ionis Pharmaceuticals by 12.3% during the 1st quarter. US Bancorp DE now owns 21,458 shares of the company’s stock worth $795,000 after buying an additional 2,343 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in Ionis Pharmaceuticals by 9.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,662 shares of the company’s stock worth $358,000 after acquiring an additional 831 shares during the period. Finally, MetLife Investment Management LLC acquired a new stake in Ionis Pharmaceuticals during the 1st quarter worth about $318,000. 93.86% of the stock is owned by institutional investors.

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

Featured Articles

Receive News & Ratings for Ionis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.